A new wave of researchers has joined the Oklahoma Medical Research Foundation’s scientific staff as part of the foundation’s expansion. OMRF has added seven new scientists to its staff. In addition, two research assistants have been promoted to faculty-level positions. The new researchers have come to OMRF from a variety of institutions across the U.S. […]
Development News
OMRF to host Estate Planning Seminar
The Oklahoma Medical Research Foundation is offering a free estate planning seminar for attorneys, CPAs and Financial Planners from 8:30 to 11:30 a.m. Oct. 1. Featured speakers will be Stacy Eastland, Managing Director for Goldman Sachs in Houston, and Richard Kells, a partner with Hartzog Conger Cason & Neville. The seminar curriculum has been submitted […]
OMRF to honor pair, welcome new directors
At its annual honors and awards banquet this evening, the Oklahoma Medical Research Foundation will honor researcher Rodger McEver, M.D., with its highest scientific prize and board member Burns Hargis with its Board of Directors Distinguished Service Award. At the dinner, which will be held at the Oklahoma City Golf and Country Club, OMRF will […]
Two patents issued to OMRF
The U.S. Patent and Trademark office has issued a pair of patents to the Oklahoma Medical Research Foundation. Patent number 7,335,632 is entitled “Beta-secretase inhibitors and methods of use thereof.” The invention covers novel enzyme inhibitors and their use for the treatment of Alzheimer’s disease. The invention stems from the work of OMRF’s Jordan Tang, […]
Noble Foundation donates $6 million to OMRF
The Samuel Roberts Noble Foundation has made a gift of $6 million to the Oklahoma Medical Research Foundation, the two foundations announced today. The gift, to be paid out in three annual installments of $2 million through 2010, will go toward construction of a new research tower at OMRF. That construction is expected to begin […]
ALEXION ACQUIRES ALL RIGHTS TO OMRF PATENTS RELATED TO SOLIRIS®
The Oklahoma Medical Research Foundation (“OMRF”) and Alexion Pharmaceuticals, Inc. (“Alexion,” Nasdaq: ALXN) today announced that Alexion has agreed to acquire from OMRF all rights to certain patents related to complement-inhibition technology. Background The patents cover inventions made by OMRF in the 1980s relating to the treatment of complement system mediated disorders, to which Alexion […]
